<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4190</article-id><article-id pub-id-type="doi">10.1186/s12879-019-4190-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Debate</subject></subj-group></article-categories><title-group><article-title>Why all blood donations should be tested for hepatitis E virus (HEV)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3244-6085</contrib-id><name><surname>Denner</surname><given-names>Joachim</given-names></name><address><email>DennerJ@rki.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pischke</surname><given-names>Sven</given-names></name><address><email>s.pischke@uke.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Steinmann</surname><given-names>Eike</given-names></name><address><email>eike.steinmann@ruhr-uni-bochum.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bl&#x000fc;mel</surname><given-names>Johannes</given-names></name><address><email>Johannes.Bluemel@pei.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Glebe</surname><given-names>Dieter</given-names></name><address><email>Dieter.Glebe@viro.med.uni-giessen.de</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0940 3744</institution-id><institution-id institution-id-type="GRID">grid.13652.33</institution-id><institution>Robert Koch Institute, </institution></institution-wrap>Nordufer 20, 13353 Berlin, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>1. Medizinische Klinik, </institution><institution>Universit&#x000e4;tsklinikum Hamburg-Eppendorf, </institution></institution-wrap>Martinistrasse 52, 20246 Hamburg, Germany </aff><aff id="Aff3"><label>3</label>Ruhr-Universit&#x000e4;t Bochum, Universit&#x000e4;tsstra&#x000df;e 150, 44801 Bochum, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1019 0926</institution-id><institution-id institution-id-type="GRID">grid.425396.f</institution-id><institution>Paul-Ehrlich-Institut, </institution></institution-wrap>Paul-Ehrlich-Stra&#x000df;e 51-59, 63225 Langen, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.452463.2</institution-id><institution>Institute of Medical Virology, National Reference Centre for Hepatitis B and D Viruses, </institution><institution>German Center for Infection Research (DZIF), </institution></institution-wrap>Schubertstr. 81, Justus-Liebig-Universit&#x000e4;t Giessen, 35392 Giessen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>19</volume><elocation-id>541</elocation-id><history><date date-type="received"><day>7</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hepatitis E is a liver disease caused by a small RNA virus known as hepatitis E virus (HEV). Four major genotypes infect humans, of which genotype 1 and 2 (HEV-1, HEV-2) are endemic mainly in Asia and responsible for waterborne epidemics. HEV-3 and HEV-4 are widely distributed in pigs and can be transmitted to humans mainly by undercooked meat, and contact with pigs. HEV-3 is the main genotype in industrialised countries with moderate climate conditions and object of this debate.</p></sec><sec><title>Main text</title><p id="Par2">Whereas an HEV-3 infection in healthy humans is mostly asymptomatic, HEV-3 can induce chronic infection in immunocompromised individuals and acute-on-chronic liver failure (ACLF) in patients with underlying liver diseases. The number of reported cases of HEV-infections in industrialised nations increased significantly in the last years. Since HEV-3 has been transmitted by blood transfusion to other humans, testing of blood donors has been introduced or introduction is being discussed in some industrialised countries. In this article we summarise the arguments in favour of testing all blood donations for HEV-3.</p></sec><sec><title>Conclusion</title><p id="Par3">The number of HEV infection in the population and the possibility of HEV transmission by blood transfusion are increasing. Transmission by blood transfusion can be dangerous for the recipients considering their immunosuppressive status, underlying disease or other circumstances requiring blood transfusion. This argues in favour of testing all blood donations for HEV-3 to prevent transmission.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis E virus</kwd><kwd>Blood donations</kwd><kwd>Blood transfusion</kwd><kwd>Safety</kwd><kwd>Blood testing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par13">Blood transfusion is a lifesaving procedure to replace blood cells or plasma lost through severe bleeding, e.g., during surgery when blood loss occurs. It is also used in anemic patients as an essential part of treatment. In 2014, nearly 3.8 million units of packed red blood cells, 485,000 thrombocyte or platelet concentrates, and 796,000&#x02009;units plasma were used for transfusions in Germany [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par14">In order to avoid transmission of microorganisms from the donor to the recipient, strong regulations are in force. All donations in Germany must be tested for antibodies against human immunodeficiency virus 1 (HIV-1) and HIV-2, against human hepatitis C virus (HCV), against human hepatitis B core antigen (HBcAg), as well as for human hepatitis B surface antigen (HBsAg) and for the genomes of HCV and HIV using nucleic acid testing (NAT) [<xref ref-type="bibr" rid="CR2">2</xref>]. Thus, transfusion-associated transmissions of these viruses are rare [<xref ref-type="bibr" rid="CR3">3</xref>]. Also transmission of other viruses including West Nile virus (WNV), human T cell lymphotropic virus (HTLV), rabies virus as well as of parasites (mainly malaria) and bacteria has been reported with a very low risk [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par15">In Germany, testing of all blood donations for HEV is in preparation to be introduced. A nationwide HEV RNA universal screening of blood donations has already been introduced in Ireland, the UK, Japan and the Netherlands. In Switzerland, nucleic acid screening of all blood products for HEV started in November 2018 [<xref ref-type="bibr" rid="CR4">4</xref>]. Blood authorities in Greece, Portugal, Italy, France and Spain are evaluating the situation [<xref ref-type="bibr" rid="CR5">5</xref>]. Recently, the responsible German authority, the Paul-Ehrlich-Institut, recommended testing all blood donations for HEV. Here, we discuss the relative risk, posed by HEV transmission via transfusion and summarise the major arguments recommending the testing of all blood donations for HEV.</p></sec><sec id="Sec2"><title>HEV - biology and prevalence</title><p id="Par16">HEV is a single-stranded, positive-sense RNA virus classified in the family <italic>Hepeviridae</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. The HEV particles present in feces and bile are nonenveloped, while those in circulating blood and culture supernatants are covered with a cellular membrane, similar to enveloped viruses and called quasi-enveloped [<xref ref-type="bibr" rid="CR7">7</xref>]. There are eight genotypes of HEV: HEV-1 and HEV-2 are primarily human viruses, whereas HEV-3 and HEV-4 were found in pigs, humans and other animals. HEV-5 and HEV-6 were described only in wild boars in Japan, HEV-7 was found in a dromedary camels and HEV-8 in Bactrian camels [<xref ref-type="bibr" rid="CR8">8</xref>]. HEV-1 and HEV-2 are endemic in regions in Asia and Africa, the major source of infection is contaminated water (for review see [<xref ref-type="bibr" rid="CR6">6</xref>]). HEV-3 and HEV-4 are zoonotic viruses transmitted to humans mainly by direct contact with pigs or eating undercooked pork. Seroprevalences of HEV-3 in domestic pigs were estimated between 5 and 100% [<xref ref-type="bibr" rid="CR9">9</xref>]. The detection of viral RNA and virus-specific antibodies depends significantly on the analysed pig material, the age of the animals and the detection methods (PCR, real-time PCR, ELISA and Western blot analysis) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par17">Usually pigs are infected at an early age after the loss of the maternal antibodies, a peak of viral excretion in pig fecal samples is detected between week three and eight after weaning, the excretion decreases with the appearance of antibodies. Detection of viral RNA in serum samples is less frequent than in liver and fecal samples [<xref ref-type="bibr" rid="CR9">9</xref>]. HEV-7 was also found in a liver transplanted patient regularly consuming camel meat and milk [<xref ref-type="bibr" rid="CR13">13</xref>]. HEV infections have little impact on animal health, the animals have no obvious symptoms, however co-infection with other viruses may increase the amount and the duration of HEV secretion or induce even fatal diseases [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec3"><title>Transmission of HEV-3 in pigs and humans</title><p id="Par18">Whereas oral-fecal transmission is the major way of HEV transmission in pigs, transmission via the placenta was also detected [<xref ref-type="bibr" rid="CR15">15</xref>]. Contact with pigs and the consumption of undercooked pork meat is the main way of transmission of HEV-3 to humans. HEV was also found in wild boars [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] and screening of wild boar hunters, forest workers and pet pig holders gave good evidence that HEV is transmitted by contact with pigs and wild boars [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Many reports describe the detection of HEV RNA in pig liver, meat and meat products intended for human consumption (for review see [<xref ref-type="bibr" rid="CR6">6</xref>]). In addition, HEV infections have been reported after consumption of shellfish and vegetables, obviously due to a contamination with pig manure [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Transmission has also been reported after consumption of wild boar meat [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par19">The seroprevalence of HEV-3 in the general population of Western countries has been shown to differ, partially due to the use of different assays [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par20">The HEV seroprevalence and viremia in blood donors was also shown to differ in Western countries (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. In the Southwest of France even 52% positive donors were found, here mainly due to the consumption of undercooked <italic>figatellu</italic> liver sausages [<xref ref-type="bibr" rid="CR27">27</xref>]. Studies in Germany showed an anti-HEV IgG prevalence of 6.8% [<xref ref-type="bibr" rid="CR41">41</xref>], the rate of HEV-positive donations was 1:4525 [<xref ref-type="bibr" rid="CR42">42</xref>] and hepatitis E viraemia was found at a relatively high rate of 0.12% among blood donors in 2018 [<xref ref-type="bibr" rid="CR42">42</xref>]. In comparison with Europe and the United States, the seroprevalence was lower in Latin America [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In Switzerland on average 29.4% of blood samples were positive, the seroprevalence increased with age (30.7% of males and 34.2% of women over 60&#x02009;years old) [<xref ref-type="bibr" rid="CR4">4</xref>]. An increase of seropositive donors with age was also observed in France [<xref ref-type="bibr" rid="CR27">27</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>HEV seroprevalence and viremia in blood donors in Western countries</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Country</th><th>HEV IgG positive (%)</th><th>RNA positive</th><th>Reference</th><th>Year of publication</th></tr></thead><tbody><tr><td>Germany</td><td>29.5</td><td>1:1200</td><td>[<xref ref-type="bibr" rid="CR26">26</xref>]</td><td>2012</td></tr><tr><td rowspan="2">France</td><td rowspan="2">22.4</td><td>1:2218</td><td>[<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td><td>2014, 2016</td></tr><tr><td>1:744</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>2017</td></tr><tr><td rowspan="2">The Netherlands</td><td rowspan="2">27.0</td><td>1:2671</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>2012</td></tr><tr><td>1.600</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td>2015</td></tr><tr><td rowspan="2">England</td><td rowspan="2">12.0</td><td>1:2848</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>]</td><td>2011</td></tr><tr><td>1:7000</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>2012</td></tr><tr><td>Scotland</td><td rowspan="2">4.7</td><td>1:14520</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td>2013</td></tr><tr><td>Denmark</td><td>1:2330</td><td>[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td>2016</td></tr><tr><td>Spain</td><td>19.9</td><td>1:3333</td><td>[<xref ref-type="bibr" rid="CR36">36</xref>]</td><td>2015</td></tr></tbody></table></table-wrap></p><p id="Par21">Due to the high prevalence in blood donors, transmission of HEV by blood transfusion has been observed [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>], but not all patients receiving HEV-positive blood got infected [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The infectivity of HEV-contaminated components for transfusion was in one study 50% [<xref ref-type="bibr" rid="CR48">48</xref>] and seems to depend upon the virus load [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. HEV transmission depends not only on the virus load, but also on the blood component given and on the presence of antibodies in the preparation [<xref ref-type="bibr" rid="CR33">33</xref>]. Overall, donations containing antibody were less likely to transmit. HEV transmission was also associated with organ transplantation, but only in single cases [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]. The prevalence of persistent HEV infection in patients with solid organ transplantation in Western Europe varies between 0.7 and 3.2% [<xref ref-type="bibr" rid="CR52">52</xref>]. The different observed incidences strongly depend on the respective antibody test applied in the respective study.</p><p id="Par22">Most infections of immunocompetent humans with HEV-3 are asymptomatic, in rare cases a mild anicteric illness and a moderate hepatitis were reported. In some cases an acute hepatitis by red blood cell transfusion was described in immunocompetent subjects [<xref ref-type="bibr" rid="CR53">53</xref>]. In a patient with thrombotic thrombocytopenic purpura (TTP), an acute HEV infection by cryosupernatant plasma triggered exacerbation of the TTP [<xref ref-type="bibr" rid="CR54">54</xref>]. HEV infection becomes chronic in patients who are immunosuppressed (HIV-infection, transplantation, chemotherapy, rheumatic diseases), however chronic HEV infection was also observed in an immunocompetent patient with a history of systemic lupus erythematosus [<xref ref-type="bibr" rid="CR55">55</xref>]. Neurological manifestations caused by HEV infections have been reported, but they are still not well analysed [<xref ref-type="bibr" rid="CR56">56</xref>]. In patients with underlying liver disease, a severe hepatitis occurs [<xref ref-type="bibr" rid="CR19">19</xref>]. HEV may be an immunosuppressive virus. There is evidence in a pig model of chronic HEV infection that HEV actively suppressed cellular immune responses [<xref ref-type="bibr" rid="CR57">57</xref>] and increased levels of the immunosuppressive IL-10 have been found in HEV-infected individuals [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par23">HEV infected individuals can be treated with the antiviral ribavirin and for prophylaxis, a human vaccine, at least against HEV-1, was developed. However the efficacy against HEV-3 has still not been specifically tested and this vaccine has no approval outside of China [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. There is evidence that the number of reported HEV-3 infections increases not only due to greater awareness and better testing, but also due to a real increase in infection rates [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. However, in Switzerland the number of human infections declined [<xref ref-type="bibr" rid="CR40">40</xref>]. Within the specified region of the Swiss Bern canton, overall prevalence has declined over two decades from 30.3% in 1997/98 to 27.0% in 2006 and 22.3% in 2015/6 [<xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec4"><title>The need of testing of all blood donations</title><p id="Par24">As mentioned above, several reports have described transfusion-transmitted HEV infections [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. In one case, HEV transmission was associated with fatal hepatitis in a Japanese cancer patient [<xref ref-type="bibr" rid="CR62">62</xref>]. However, it is obvious that the risk of infection through meat consumption is much higher compared with transmission by blood transfusion. Screening blood donations will not prevent most cases of HEV transmission, but it will significantly reduce the risk for the transfusion recipients, which are either immunosuppressed and/or suffering from different diseases. In addition, there is a great difference between a person who takes up the virus orally and a person who gets infected intravenously. In the case of oral uptake there may be some protection by the acidic environment of the stomach and the mucosal barrier in the gut. Immunocompromised patients need often multiple transfusions, which increases the risk from transmission [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par25">HEV was detected in 1 of 815 blood donations in Germany [<xref ref-type="bibr" rid="CR45">45</xref>] and is 100 times more prevalent compared with HIV, HCV and HBV combined. Risk estimations considering both, the HEV prevalence and clinical risk for immunocompromised patients [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] led to introduction of blood screening for HEV in the Netherlands and Germany. Analysing the cost-effectiveness of the screening of blood donations for HEV in the Netherlands, the authors came to the conclusion that preventing HEV transmission by screening of blood donations appears not excessively expensive compared to other blood screening measures [<xref ref-type="bibr" rid="CR63">63</xref>]. However, since only a small number of HEV infections are due to blood transfusions, the overall impact on HEV disease burden will be small [<xref ref-type="bibr" rid="CR63">63</xref>]. To reduce de novo infections in general, several strategies have been proposed [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par26">It may be assumed that it may be sufficient to test only the blood donations for people at risk, e.g., immunosuppressed organ transplant recipients and recipients of haematopoietic stem cells. Such a limited testing seemed cost effective while protecting patients at major risk. However, there are several arguments for universal screening of all blood donations. First, the category &#x0201c;people at risk&#x0201d; is difficult to define due to individual variability. Cancer patients under chemotherapy, HIV infected individuals, and patients with rheumatoid arthritis and other rheumatic diseases under immunosuppressive treatment should also be included. The fatal outcome of a transfusion-transmitted infection of a cancer patient in Japan [<xref ref-type="bibr" rid="CR62">62</xref>] underlines that the risk-group should not be limited to transplant patients alone. Second, even immunocompetent patients may suffer from acute HEV-infection or induced complications under circumstances requiring blood or plasma transfusion [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Third, the handling of two separate types of blood donations would increase logistical cost and may even lead to product losses due to the stockpiling of tested and non-tested donations. For example, in the case more tested material is required, stored non-tested material will not be used and may expire and vice versa. Fourth, it may be very difficult or even impossible for a physician to assign a patient to an HEV risk in an emergency requiring transfusion.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par27">HEV-contaminated food is the main source of HEV transmission to humans in Europe and other industrialised countries with moderate climate conditions. However, transmission by blood transfusion can be dangerous for the recipients considering their immunosuppressive status, underlying disease or other circumstances requiring blood transfusion. Several of the arguments discussed above in detail argue in favour of testing all blood donations for HEV-3 to prevent transmission. Based on these arguments, blood donor testing has been introduced in several industrialised countries, including recently Germany.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACLF</term><def><p id="Par4">Acute-on-chronic liver failure</p></def></def-item><def-item><term>HBcAg</term><def><p id="Par5">Hepatitis B core antigen</p></def></def-item><def-item><term>HBsAg</term><def><p id="Par6">Hepatitis B surface antigen</p></def></def-item><def-item><term>HCV</term><def><p id="Par7">Hepatitis C virus</p></def></def-item><def-item><term>HEV</term><def><p id="Par8">Hepatitis E virus</p></def></def-item><def-item><term>HIV</term><def><p id="Par9">Human immunodeficiency virus</p></def></def-item><def-item><term>HTLV</term><def><p id="Par10">Human T cell lymphotropic virus</p></def></def-item><def-item><term>NAT</term><def><p id="Par11">Nucleic acid testing</p></def></def-item><def-item><term>WNV</term><def><p id="Par12">West Nile virus</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors would like to thank Prof. H. Hengel (GfV) and Prof. H. Fickenscher (DVV) for critical review of the manuscript. All authors are members of the commission &#x0201c;Virus safety in transfusion and transplantation&#x0201d; of the Society for Virology in Germany (GfV) and the German Association for the Control of Virus Diseases (DVV).</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JD proposed and planned the article, all authors (JD, SP, ES, JB, DG) contributed equally, the authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par28">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par29">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>T</given-names></name><name><surname>Amin</surname><given-names>NA</given-names></name><name><surname>Schmid</surname><given-names>G</given-names></name><name><surname>Dhingra-Kumar</surname><given-names>N</given-names></name><name><surname>Rugg</surname><given-names>D</given-names></name></person-group><article-title>Progress in global blood safety for HIV</article-title><source>J Acquir Immune Defic Syndr</source><year>2009</year><volume>52</volume><issue>Suppl 2</issue><fpage>S127</fpage><lpage>S131</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181baf0ac</pub-id><pub-id pub-id-type="pmid">19901625</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie H&#x000e4;motherapie). Bundes&#x000e4;rztekammer, (guideline for the production of blood and blood components and the use of blood products (guideline for hemotherapy). German Medical Association), 2017. <ext-link ext-link-type="uri" xlink:href="https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/MuE/Richtlinie_Haemotherapie_2017.pdf">https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/MuE/Richtlinie_Haemotherapie_2017.pdf</ext-link>. Accessed 17 June 2019.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkin</surname><given-names>HA</given-names></name><name><surname>Busch</surname><given-names>P</given-names></name></person-group><article-title>Transfusion-associated infections: 50 years of relentless challenges and remarkable progress</article-title><source>Transfusion.</source><year>2010</year><volume>50</volume><fpage>2080</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02851.x</pub-id><pub-id pub-id-type="pmid">20738828</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Niederhauser C, Widmer N, Hotz M, Tinguely C, Fontana S, Allemann G, Borri M, Infanti L, Sarraj A, Sigle J, Stalder M, Thierbach J, Waldvogel S, Wiengand T, Z&#x000fc;ger M, Gowland P. Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016. Euro Surveill. 2018;23(35).</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Domanovi&#x00107; D, Tedder R, Bl&#x000fc;mel J, Zaaijer H, Gallian P, Niederhauser C, Sauleda Oliveras S, O'Riordan J, Boland F, Harritsh&#x000f8;j L, Nascimento MSJ, Ciccaglione AR, Politis C, Adlhoch C, Flan B, Oualikene-Gonin W, Rautmann G, Strengers P, Hewitt P. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill. 2017;22(16).</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johne</surname><given-names>R</given-names></name><name><surname>Dremsek</surname><given-names>P</given-names></name><name><surname>Reetz</surname><given-names>J</given-names></name><name><surname>Heckel</surname><given-names>G</given-names></name><name><surname>Hess</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>RG</given-names></name></person-group><article-title>Hepeviridae: an expanding family of vertebrate viruses</article-title><source>Infect Genet Evol</source><year>2014</year><volume>27</volume><fpage>212</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2014.06.024</pub-id><pub-id pub-id-type="pmid">25050488</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Nagashima S, Takahashi M, Kobayashi T, Tanggis NT, Nishiyama T, Primadharsini PP, Okamoto H. Characterization of the quasi-enveloped hepatitis E virus particles released by the cellular Exosomal pathway. J Virol. 2017;(22):91.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><name><surname>Lau</surname><given-names>SK</given-names></name><name><surname>Teng</surname><given-names>JL</given-names></name><name><surname>Cao</surname><given-names>KY</given-names></name><name><surname>Wernery</surname><given-names>U</given-names></name><name><surname>Schountz</surname><given-names>T</given-names></name><name><surname>Chiu</surname><given-names>TH</given-names></name><name><surname>Tsang</surname><given-names>AK</given-names></name><name><surname>Wong</surname><given-names>PC</given-names></name><name><surname>Wong</surname><given-names>EY</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>New hepatitis E virus genotype in Bactrian camels, Xinjiang, China, 2013</article-title><source>Emerg Infect Dis</source><year>2016</year><volume>22</volume><issue>12</issue><fpage>2219</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.3201/eid2212.160979</pub-id><pub-id pub-id-type="pmid">27869607</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Doceul</surname><given-names>V</given-names></name><name><surname>Bagdassarian</surname><given-names>E</given-names></name><name><surname>Johne</surname><given-names>R</given-names></name></person-group><article-title>Recent knowledge on hepatitis E virus in Suidae reservoirs and transmission routes to human</article-title><source>Vet Res</source><year>2017</year><volume>48</volume><issue>1</issue><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s13567-017-0483-9</pub-id><pub-id pub-id-type="pmid">29157309</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendall</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>V</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Dalton</surname><given-names>H</given-names></name></person-group><article-title>A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries</article-title><source>J Med Virol</source><year>2010</year><volume>82</volume><issue>5</issue><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1002/jmv.21656</pub-id><pub-id pub-id-type="pmid">20336757</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Absi</surname><given-names>ES</given-names></name><name><surname>Al-Sadeq</surname><given-names>DW</given-names></name><name><surname>Younis</surname><given-names>MH</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name><name><surname>Abdalla</surname><given-names>OM</given-names></name><name><surname>Mesleh</surname><given-names>AG</given-names></name><name><surname>Hadwan</surname><given-names>TA</given-names></name><name><surname>Amimo</surname><given-names>JO</given-names></name><name><surname>Thalib</surname><given-names>L</given-names></name><name><surname>Nasrallah</surname><given-names>GK</given-names></name></person-group><article-title>Performance evaluation of five commercial assays in assessing seroprevalence of HEV antibodies among blood donors</article-title><source>J Med Microbiol</source><year>2018</year><volume>67</volume><issue>9</issue><fpage>1302</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000807</pub-id><pub-id pub-id-type="pmid">30051802</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dremsek</surname><given-names>P</given-names></name><name><surname>Joel</surname><given-names>S</given-names></name><name><surname>Baechlein</surname><given-names>C</given-names></name><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Schielke</surname><given-names>A</given-names></name><name><surname>Ziller</surname><given-names>M</given-names></name><name><surname>D&#x000fc;rrwald</surname><given-names>R</given-names></name><name><surname>Renner</surname><given-names>C</given-names></name><name><surname>Groschup</surname><given-names>MH</given-names></name><name><surname>Johne</surname><given-names>R</given-names></name><name><surname>Krumbholz</surname><given-names>A</given-names></name><name><surname>Ulrich</surname><given-names>RG</given-names></name></person-group><article-title>Hepatitis E virus seroprevalence of domestic pigs in Germany determined by a novel in-house and two reference ELISAs</article-title><source>J Virol Methods</source><year>2013</year><volume>190</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2013.03.010</pub-id><pub-id pub-id-type="pmid">23523888</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Tan</surname><given-names>BH</given-names></name><name><surname>Teo</surname><given-names>EC</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name><name><surname>Dan</surname><given-names>YY</given-names></name><name><surname>Wee</surname><given-names>A</given-names></name><name><surname>Aw</surname><given-names>PP</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Tan</surname><given-names>CK</given-names></name><name><surname>Purdy</surname><given-names>MA</given-names></name><name><surname>Teo</surname><given-names>CG</given-names></name></person-group><article-title>Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and Milk</article-title><source>Gastroenterology.</source><year>2016</year><volume>150</volume><issue>2</issue><fpage>355</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.10.048</pub-id><pub-id pub-id-type="pmid">26551551</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>She</surname><given-names>R</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Soomro</surname><given-names>MH</given-names></name></person-group><article-title>Fatal disease associated with swine hepatitis E virus and porcine circovirus 2 co-infection in four weaned pigs in China</article-title><source>BMC Vet Res</source><year>2015</year><volume>11</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s12917-015-0375-z</pub-id><pub-id pub-id-type="pmid">25889526</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morozov</surname><given-names>VA</given-names></name><name><surname>Morozov</surname><given-names>AV</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Barkai</surname><given-names>U</given-names></name><name><surname>Bornstein</surname><given-names>S</given-names></name><name><surname>Denner</surname><given-names>J</given-names></name></person-group><article-title>Extended microbiological characterization of G&#x000f6;ttingen Minipigs in the context of xenotransplantation: detection and vertical transmission of hepatitis E virus</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>10</issue><fpage>e0139893</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0139893</pub-id><pub-id pub-id-type="pmid">26466154</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schielke</surname><given-names>A</given-names></name><name><surname>Sachs</surname><given-names>K</given-names></name><name><surname>Lierz</surname><given-names>M</given-names></name><name><surname>Appel</surname><given-names>B</given-names></name><name><surname>Jansen</surname><given-names>A</given-names></name><name><surname>Johne</surname><given-names>R</given-names></name></person-group><article-title>Detection of hepatitis E virus in wild boars of rural and urban regions in Germany and whole genome characterization of an endemic strain</article-title><source>Virol J</source><year>2009</year><volume>6</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-58</pub-id><pub-id pub-id-type="pmid">19442307</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wid&#x000e9;n</surname><given-names>F</given-names></name><name><surname>Sundqvist</surname><given-names>L</given-names></name><name><surname>Matyi-Toth</surname><given-names>A</given-names></name><name><surname>Metreveli</surname><given-names>G</given-names></name><name><surname>Bel&#x000e1;k</surname><given-names>S</given-names></name><name><surname>Hallgren</surname><given-names>G</given-names></name><name><surname>Norder</surname><given-names>H</given-names></name></person-group><article-title>Molecular epidemiology of hepatitis E virus in humans, pigs and wild boars in Sweden</article-title><source>Epidemiol Infect</source><year>2011</year><volume>139</volume><issue>3</issue><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1017/S0950268810001342</pub-id><pub-id pub-id-type="pmid">20546635</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumbholz</surname><given-names>A</given-names></name><name><surname>Mohn</surname><given-names>U</given-names></name><name><surname>Lange</surname><given-names>J</given-names></name><name><surname>Motz</surname><given-names>M</given-names></name><name><surname>Wenzel</surname><given-names>JJ</given-names></name><name><surname>Jilg</surname><given-names>W</given-names></name><name><surname>Walther</surname><given-names>M</given-names></name><name><surname>Straube</surname><given-names>E</given-names></name><name><surname>Wutzler</surname><given-names>P</given-names></name><name><surname>Zell</surname><given-names>R</given-names></name></person-group><article-title>Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs</article-title><source>Med Microbiol Immunol</source><year>2012</year><volume>201</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1007/s00430-011-0210-5</pub-id><pub-id pub-id-type="pmid">21773797</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartl</surname><given-names>Johannes</given-names></name><name><surname>Wehmeyer</surname><given-names>Malte</given-names></name><name><surname>Pischke</surname><given-names>Sven</given-names></name></person-group><article-title>Acute Hepatitis E: Two Sides of the Same Coin</article-title><source>Viruses</source><year>2016</year><volume>8</volume><issue>11</issue><fpage>299</fpage><pub-id pub-id-type="doi">10.3390/v8110299</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommerkorn</surname><given-names>FM</given-names></name><name><surname>Schauer</surname><given-names>B</given-names></name><name><surname>Schreiner</surname><given-names>T</given-names></name><name><surname>Fickenscher</surname><given-names>H</given-names></name><name><surname>Krumbholz</surname><given-names>A</given-names></name></person-group><article-title>Performance of hepatitis E virus (HEV)-antibody tests: a comparative analysis based on samples from individuals with direct contact to domestic pigs or wild boar in Germany</article-title><source>Med Microbiol Immunol 2017</source><year>2017</year><volume>206</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s00430-017-0503-4</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grodzki</surname><given-names>M</given-names></name><name><surname>Schaeffer</surname><given-names>J</given-names></name><name><surname>Piquet</surname><given-names>JC</given-names></name><name><surname>Le Saux</surname><given-names>JC</given-names></name><name><surname>Chev&#x000e9;</surname><given-names>J</given-names></name><name><surname>Ollivier</surname><given-names>J</given-names></name><name><surname>Le Pendu</surname><given-names>J</given-names></name><name><surname>Le Guyader</surname><given-names>FS</given-names></name></person-group><article-title>Bioaccumulation efficiency, tissue distribution, and environmental occurrence of hepatitis E virus in bivalve shellfish from France</article-title><source>Appl Environ Microbiol</source><year>2014</year><volume>80</volume><issue>14</issue><fpage>4269</fpage><lpage>4276</lpage><pub-id pub-id-type="doi">10.1128/AEM.00978-14</pub-id><pub-id pub-id-type="pmid">24795382</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hara</surname><given-names>Z</given-names></name><name><surname>Crossan</surname><given-names>C</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name><name><surname>Scobie</surname><given-names>L</given-names></name></person-group><article-title>First report of the presence of hepatitis E virus in Scottish-harvested shellfish purchased at retail level</article-title><source>Food Environ Virol</source><year>2018</year><volume>10</volume><issue>2</issue><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1007/s12560-018-9337-5</pub-id><pub-id pub-id-type="pmid">29442296</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinos</surname><given-names>P</given-names></name><name><surname>Kozyra</surname><given-names>I</given-names></name><name><surname>Lazic</surname><given-names>S</given-names></name><name><surname>Bouwknegt</surname><given-names>M</given-names></name><name><surname>Rutjes</surname><given-names>S</given-names></name><name><surname>Willems</surname><given-names>K</given-names></name><name><surname>Moloney</surname><given-names>R</given-names></name><name><surname>de Roda Husman</surname><given-names>AM</given-names></name><name><surname>Kaupke</surname><given-names>A</given-names></name><name><surname>Legaki</surname><given-names>E</given-names></name><name><surname>D'Agostino</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>N</given-names></name><name><surname>Rze&#x0017c;utka</surname><given-names>A</given-names></name><name><surname>Petrovic</surname><given-names>T</given-names></name><name><surname>Vantarakis</surname><given-names>A</given-names></name></person-group><article-title>Harmonised investigation of the occurrence of human enteric viruses in the leafy green vegetable supply chain in three European countries</article-title><source>Food Environ Virol.</source><year>2012</year><volume>4</volume><issue>4</issue><fpage>179</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1007/s12560-012-9087-8</pub-id><pub-id pub-id-type="pmid">23412890</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Faber M, Askar M, Stark K. Case-control study on risk factors for acute hepatitis E in Germany, 2012 to 2014. Euro Surveill. 2018;23(19).</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>JJ</given-names></name><name><surname>Preiss</surname><given-names>J</given-names></name><name><surname>Schemmerer</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>B</given-names></name><name><surname>Jilg</surname><given-names>W</given-names></name></person-group><article-title>Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates</article-title><source>J Infect Dis</source><year>2013</year><volume>207</volume><issue>3</issue><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis688</pub-id><pub-id pub-id-type="pmid">23148290</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>T</given-names></name><name><surname>Diekmann</surname><given-names>J</given-names></name><name><surname>Johne</surname><given-names>R</given-names></name><name><surname>Eberhardt</surname><given-names>M</given-names></name><name><surname>Knabbe</surname><given-names>C</given-names></name><name><surname>Dreier</surname><given-names>J</given-names></name></person-group><article-title>Novel approach for detection of hepatitis E virus infection in German blood donors</article-title><source>J Clin Microbiol</source><year>2012</year><volume>50</volume><issue>8</issue><fpage>2708</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1128/JCM.01119-12</pub-id><pub-id pub-id-type="pmid">22675127</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Dimeglio</surname><given-names>C</given-names></name><name><surname>Saune</surname><given-names>K</given-names></name><name><surname>Arnaud</surname><given-names>C</given-names></name><name><surname>Pelletier</surname><given-names>B</given-names></name><name><surname>Morel</surname><given-names>P</given-names></name><name><surname>Legrand</surname><given-names>D</given-names></name><name><surname>Tiberghien</surname><given-names>P</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>A nationwide survey of hepatitis E viral infection in French blood donors</article-title><source>Hepatology.</source><year>2016</year><volume>63</volume><issue>4</issue><fpage>1145</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1002/hep.28436</pub-id><pub-id pub-id-type="pmid">27008201</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Piquet</surname><given-names>Y</given-names></name><name><surname>Saun&#x000e9;</surname><given-names>K</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Assal</surname><given-names>A</given-names></name><name><surname>Tiberghien</surname><given-names>P</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E virus infections in blood donors</article-title><source>France Emerg Infect Dis</source><year>2014</year><volume>20</volume><issue>11</issue><fpage>1914</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.3201/eid2011.140516</pub-id><pub-id pub-id-type="pmid">25340881</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Couchouron</surname><given-names>A</given-names></name><name><surname>Dupont</surname><given-names>I</given-names></name><name><surname>Fabra</surname><given-names>C</given-names></name><name><surname>Piquet</surname><given-names>Y</given-names></name><name><surname>Djoudi</surname><given-names>R</given-names></name><name><surname>Assal</surname><given-names>A</given-names></name><name><surname>Tiberghien</surname><given-names>P</given-names></name></person-group><article-title>Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors</article-title><source>Transfusion.</source><year>2017</year><volume>57</volume><issue>1</issue><fpage>223</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1111/trf.13889</pub-id><pub-id pub-id-type="pmid">28097700</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slot</surname><given-names>E</given-names></name><name><surname>Hogema</surname><given-names>B</given-names></name><name><surname>Riezebos-Brilman</surname><given-names>A</given-names></name><name><surname>Kok</surname><given-names>T</given-names></name><name><surname>Molier</surname><given-names>M</given-names></name><name><surname>Zaaijer</surname><given-names>H</given-names></name></person-group><article-title>Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012</article-title><source>Eurosurveillance</source><year>2013</year><volume>18</volume><issue>31</issue><fpage>20550</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES2013.18.31.20550</pub-id><pub-id pub-id-type="pmid">23929229</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaaijer</surname><given-names>HL</given-names></name></person-group><article-title>No artefact, hepatitis E is emerging</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>654</fpage><pub-id pub-id-type="doi">10.1002/hep.27611</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beale</surname><given-names>MA</given-names></name><name><surname>Tettmar</surname><given-names>K</given-names></name><name><surname>Szypulska</surname><given-names>R</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name></person-group><article-title>Ijaz S. is there evidence of recent hepatitis E virus infection in English and north welsh blood donors?</article-title><source>Vox Sang</source><year>2011</year><volume>100</volume><issue>3</issue><fpage>340</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2010.01412.x</pub-id><pub-id pub-id-type="pmid">21392024</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>PE</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Brailsford</surname><given-names>SR</given-names></name><name><surname>Brett</surname><given-names>R</given-names></name><name><surname>Dicks</surname><given-names>S</given-names></name><name><surname>Haywood</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>IT</given-names></name><name><surname>Kitchen</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Poh</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>K</given-names></name><name><surname>Tettmar</surname><given-names>KI</given-names></name><name><surname>Tossell</surname><given-names>J</given-names></name><name><surname>Ushiro-Lumb</surname><given-names>I</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name></person-group><article-title>Hepatitis E virus in blood components: a prevalence and transmission study in Southeast England</article-title><source>Lancet.</source><year>2014</year><volume>384</volume><issue>9956</issue><fpage>1766</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61034-5</pub-id><pub-id pub-id-type="pmid">25078306</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Crossan</surname><given-names>C</given-names></name><name><surname>Blatchford</surname><given-names>O</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Scobie</surname><given-names>L</given-names></name><name><surname>Petrik</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E virus in Scottish blood donors</article-title><source>Vox Sang</source><year>2013</year><volume>105</volume><issue>4</issue><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1111/vox.12056</pub-id><pub-id pub-id-type="pmid">23763589</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harritsh&#x000f8;j</surname><given-names>LH</given-names></name><name><surname>Holm</surname><given-names>DK</given-names></name><name><surname>Saekmose</surname><given-names>SG</given-names></name><name><surname>Jensen</surname><given-names>BA</given-names></name><name><surname>Hogema</surname><given-names>BM</given-names></name><name><surname>Fischer</surname><given-names>TK</given-names></name><name><surname>Midgley</surname><given-names>SE</given-names></name><name><surname>Krog</surname><given-names>JS</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Ullum</surname><given-names>H</given-names></name></person-group><article-title>Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors</article-title><source>Transfusion.</source><year>2016</year><volume>56</volume><issue>9</issue><fpage>2225</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1111/trf.13700</pub-id><pub-id pub-id-type="pmid">27385646</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauleda</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Bes</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>A</given-names></name><name><surname>Cory</surname><given-names>R</given-names></name><name><surname>Babizki</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Lindquist</surname><given-names>A</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><name><surname>Vang</surname><given-names>L</given-names></name><name><surname>Piron</surname><given-names>M</given-names></name><name><surname>Casamitjana</surname><given-names>N</given-names></name><name><surname>Koppelman</surname><given-names>M</given-names></name><name><surname>Danzig</surname><given-names>L</given-names></name><name><surname>Linnen</surname><given-names>JM</given-names></name></person-group><article-title>Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain)</article-title><source>Transfusion.</source><year>2015</year><volume>55</volume><issue>5</issue><fpage>972</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1111/trf.12929</pub-id><pub-id pub-id-type="pmid">25403913</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Bendall</surname><given-names>R</given-names></name><name><surname>Legrand-Abravanel</surname><given-names>F</given-names></name><name><surname>Saun&#x000e9;</surname><given-names>K</given-names></name><name><surname>Mi&#x000e9;douge</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>V</given-names></name><name><surname>Rech</surname><given-names>H</given-names></name><name><surname>Destruel</surname><given-names>F</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E virus antibodies in blood donors, France</article-title><source>Emerg Infect Dis</source><year>2011</year><volume>17</volume><issue>12</issue><fpage>2309</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3201/eid1712.110371</pub-id><pub-id pub-id-type="pmid">22172156</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogema</surname><given-names>BM</given-names></name><name><surname>Molier</surname><given-names>M</given-names></name><name><surname>Slot</surname><given-names>E</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name></person-group><article-title>Past and present of hepatitis E in the Netherlands</article-title><source>Transfusion.</source><year>2014</year><volume>54</volume><issue>12</issue><fpage>3092</fpage><lpage>3096</lpage><pub-id pub-id-type="doi">10.1111/trf.12733</pub-id><pub-id pub-id-type="pmid">24889277</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>PB</given-names></name><name><surname>Engle</surname><given-names>RE</given-names></name><name><surname>Hjort</surname><given-names>C</given-names></name><name><surname>Homburg</surname><given-names>KM</given-names></name><name><surname>Vach</surname><given-names>W</given-names></name><name><surname>Georgsen</surname><given-names>J</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name></person-group><article-title>Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark</article-title><source>Clin Infect Dis</source><year>2008</year><volume>47</volume><issue>8</issue><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1086/591970</pub-id><pub-id pub-id-type="pmid">18781880</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogema</surname><given-names>BM</given-names></name><name><surname>Molier</surname><given-names>M</given-names></name><name><surname>Sjerps</surname><given-names>M</given-names></name><name><surname>de Waal</surname><given-names>M</given-names></name><name><surname>van Swieten</surname><given-names>P</given-names></name><name><surname>van de Laar</surname><given-names>T</given-names></name><name><surname>Molenaar-de Backer</surname><given-names>M</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name></person-group><article-title>Incidence and duration of hepatitis E virus infection in Dutch blood donors</article-title><source>Transfusion.</source><year>2016</year><volume>56</volume><issue>3</issue><fpage>722</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1111/trf.13402</pub-id><pub-id pub-id-type="pmid">26559806</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juhl</surname><given-names>D</given-names></name><name><surname>Baylis</surname><given-names>SA</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>J</given-names></name><name><surname>G&#x000f6;rg</surname><given-names>S</given-names></name><name><surname>Hennig</surname><given-names>H</given-names></name></person-group><article-title>Seroprevalence and incidence of hepatitis E virus infection in German blood donors</article-title><source>Transfusion.</source><year>2014</year><volume>54</volume><issue>1</issue><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1111/trf.12121</pub-id><pub-id pub-id-type="pmid">23441647</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baylis</surname><given-names>SA</given-names></name><name><surname>G&#x000e4;rtner</surname><given-names>T</given-names></name><name><surname>Nick</surname><given-names>S</given-names></name><name><surname>Ovemyr</surname><given-names>J</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>J</given-names></name></person-group><article-title>Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States</article-title><source>Vox Sang</source><year>2012</year><volume>103</volume><issue>1</issue><fpage>89</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2011.01583.x</pub-id><pub-id pub-id-type="pmid">22220775</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Horvatits T, Ozga AK, Westh&#x000f6;lter D, Hartl J, Manthey CF, L&#x000fc;tgehetmann M, Rauch G, Kriston L, Lohse AW, Bendall R, Wedemeyer H, Dalton HR, Pischke S. Hepatitis E seroprevalence in the Americas: a systematic review and meta-analysis. Liver Int. 2018 Apr 16.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boxall</surname><given-names>E</given-names></name><name><surname>Herborn</surname><given-names>A</given-names></name><name><surname>Kochethu</surname><given-names>G</given-names></name><name><surname>Pratt</surname><given-names>G</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>CG</given-names></name></person-group><article-title>Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country</article-title><source>Transfus Med</source><year>2006</year><volume>16</volume><issue>2</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3148.2006.00652.x</pub-id><pub-id pub-id-type="pmid">16623913</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westh&#x000f6;lter</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>J</given-names></name><name><surname>Denzer</surname><given-names>U</given-names></name><name><surname>Polywka</surname><given-names>S</given-names></name><name><surname>Ayuk</surname><given-names>F</given-names></name><name><surname>Rybczynski</surname><given-names>M</given-names></name><name><surname>Horvatits</surname><given-names>T</given-names></name><name><surname>Gundlach</surname><given-names>S</given-names></name><name><surname>Bl&#x000f6;cker</surname><given-names>J</given-names></name><name><surname>Schulze Zur Wiesch</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>N</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name><name><surname>Peine</surname><given-names>S</given-names></name><name><surname>G&#x000f6;ke</surname><given-names>B</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>L&#x000fc;tgehetmann</surname><given-names>M</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name></person-group><article-title>HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><issue>1</issue><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.02.031</pub-id><pub-id pub-id-type="pmid">29551705</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreier</surname><given-names>J</given-names></name><name><surname>Knabbe</surname><given-names>C</given-names></name><name><surname>Vollmer</surname><given-names>T</given-names></name></person-group><article-title>Transfusion-transmitted hepatitis E: NAT screening of blood donations and infectious dose</article-title><source>Front Med (Lausanne)</source><year>2018</year><volume>5</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.3389/fmed.2018.00005</pub-id><pub-id pub-id-type="pmid">29450199</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tedder</surname><given-names>RS</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Kitchen</surname><given-names>A</given-names></name><name><surname>Ushiro-Lumb</surname><given-names>I</given-names></name><name><surname>Tettmar</surname><given-names>KI</given-names></name><name><surname>Hewitt</surname><given-names>P</given-names></name><name><surname>Andrews</surname><given-names>N</given-names></name></person-group><article-title>Hepatitis E risks: pigs or blood-that is the question</article-title><source>Transfusion.</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/trf.13976</pub-id><pub-id pub-id-type="pmid">28194857</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satake</surname><given-names>M</given-names></name><name><surname>Matsubayashi</surname><given-names>K</given-names></name><name><surname>Hoshi</surname><given-names>Y</given-names></name><name><surname>Taira</surname><given-names>R</given-names></name><name><surname>Furui</surname><given-names>Y</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><name><surname>Akamatsu</surname><given-names>N</given-names></name><name><surname>Yoshizumi</surname><given-names>T</given-names></name><name><surname>Ohkohchi</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Miyoshi</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Fuse</surname><given-names>K</given-names></name><name><surname>Tadokoro</surname><given-names>K</given-names></name></person-group><article-title>Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression</article-title><source>Transfusion.</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/trf.13994</pub-id><pub-id pub-id-type="pmid">28144952</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlosser</surname><given-names>B</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Neuhaus</surname><given-names>R</given-names></name><name><surname>Pahl</surname><given-names>S</given-names></name><name><surname>Ramez</surname><given-names>B</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>DH</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Hofmann</surname><given-names>J</given-names></name></person-group><article-title>Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient</article-title><source>J Hepatol</source><year>2012</year><volume>56</volume><issue>2</issue><fpage>500</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.06.021</pub-id><pub-id pub-id-type="pmid">21798217</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Suneetha</surname><given-names>PV</given-names></name><name><surname>Baechlein</surname><given-names>C</given-names></name><name><surname>Barg-Hock</surname><given-names>H</given-names></name><name><surname>Heim</surname><given-names>A</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Schlue</surname><given-names>J</given-names></name><name><surname>Strassburg</surname><given-names>CP</given-names></name><name><surname>Lehner</surname><given-names>F</given-names></name><name><surname>Raupach</surname><given-names>R</given-names></name><name><surname>Bremer</surname><given-names>B</given-names></name><name><surname>Magerstedt</surname><given-names>P</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Seehusen</surname><given-names>F</given-names></name><name><surname>Baumgaertner</surname><given-names>W</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Grummer</surname><given-names>B</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name></person-group><article-title>Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients</article-title><source>Liver Transpl</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/lt.21958</pub-id><pub-id pub-id-type="pmid">19866448</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Greer</surname><given-names>M</given-names></name><name><surname>Hardtke</surname><given-names>S</given-names></name><name><surname>Bremer</surname><given-names>B</given-names></name><name><surname>Gisa</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Gottlieb</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E study group. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients</article-title><source>Transpl Infect Dis</source><year>2014</year><volume>16</volume><issue>2</issue><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1111/tid.12183</pub-id><pub-id pub-id-type="pmid">24438577</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ankcorn</surname><given-names>MJ</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Poh</surname><given-names>J</given-names></name><name><surname>Elsharkawy</surname><given-names>AM</given-names></name><name><surname>Smit</surname><given-names>E</given-names></name><name><surname>Cramb</surname><given-names>R</given-names></name><name><surname>Ravi</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Tedder</surname><given-names>R</given-names></name><name><surname>Neuberger</surname><given-names>J</given-names></name></person-group><article-title>Toward systematic screening for persistent hepatitis E virus infections in transplant patients</article-title><source>Transplantation.</source><year>2018</year><volume>102</volume><issue>7</issue><fpage>1139</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000002097</pub-id><pub-id pub-id-type="pmid">29953421</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riveiro-Barciela</surname><given-names>M</given-names></name><name><surname>Sauleda</surname><given-names>S</given-names></name><name><surname>Quer</surname><given-names>J</given-names></name><name><surname>Salvador</surname><given-names>F</given-names></name><name><surname>Gregori</surname><given-names>J</given-names></name><name><surname>Pir&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez-Fr&#x000ed;as</surname><given-names>F</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name></person-group><article-title>Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report</article-title><source>Transfusion.</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/trf.13876</pub-id><pub-id pub-id-type="pmid">27785789</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riveiro-Barciela</surname><given-names>M</given-names></name><name><surname>Bes</surname><given-names>M</given-names></name><name><surname>Quer</surname><given-names>J</given-names></name><name><surname>Valcarcel</surname><given-names>D</given-names></name><name><surname>Piriz</surname><given-names>S</given-names></name><name><surname>Gregori</surname><given-names>J</given-names></name><name><surname>Llorens</surname><given-names>M</given-names></name><name><surname>Salcedo</surname><given-names>MT</given-names></name><name><surname>Piron</surname><given-names>M</given-names></name><name><surname>Esteban</surname><given-names>R</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Sauleda</surname><given-names>S</given-names></name></person-group><article-title>Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin</article-title><source>Transfusion.</source><year>2018</year><volume>58</volume><issue>11</issue><fpage>2501</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1111/trf.14831</pub-id><pub-id pub-id-type="pmid">30284732</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>P</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Motamed</surname><given-names>D</given-names></name></person-group><article-title>Chronic hepatitis E in an immunocompetent patient: a case report</article-title><source>Hepatology.</source><year>2014</year><volume>59</volume><issue>1</issue><fpage>347</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1002/hep.26636</pub-id><pub-id pub-id-type="pmid">23913727</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>van Eijk</surname><given-names>JJ</given-names></name><name><surname>Mclean</surname><given-names>BN</given-names></name><name><surname>Cintas</surname><given-names>P</given-names></name><name><surname>Bendall</surname><given-names>RP</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name></person-group><article-title>Hepatitis E virus and neurological injury</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.234</pub-id><pub-id pub-id-type="pmid">26711839</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>QM</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Yugo</surname><given-names>DM</given-names></name><name><surname>Heffron</surname><given-names>CL</given-names></name><name><surname>Rogers</surname><given-names>AJ</given-names></name><name><surname>Kenney</surname><given-names>SP</given-names></name><name><surname>Tian</surname><given-names>D</given-names></name><name><surname>Matzinger</surname><given-names>SR</given-names></name><name><surname>Overend</surname><given-names>C</given-names></name><name><surname>Catanzaro</surname><given-names>N</given-names></name><name><surname>LeRoith</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Pi&#x000f1;eyro</surname><given-names>P</given-names></name><name><surname>Lindstrom</surname><given-names>N</given-names></name><name><surname>Clark-Deener</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>XJ</given-names></name></person-group><article-title>Pig model mimicking chronic hepatitis E virus infection in immunocompromised patients to assess immune correlates during chronicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><issue>27</issue><fpage>6914</fpage><lpage>6923</lpage><pub-id pub-id-type="doi">10.1073/pnas.1705446114</pub-id><pub-id pub-id-type="pmid">28630341</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saravanabalaji</surname><given-names>S</given-names></name><name><surname>Tripathy</surname><given-names>AS</given-names></name><name><surname>Dhoot</surname><given-names>RR</given-names></name><name><surname>Chadha</surname><given-names>MS</given-names></name><name><surname>Kakrani</surname><given-names>AL</given-names></name><name><surname>Arankalle</surname><given-names>VA</given-names></name></person-group><article-title>Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis e</article-title><source>Intervirology.</source><year>2009</year><volume>52</volume><issue>2</issue><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1159/000214862</pub-id><pub-id pub-id-type="pmid">19401616</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>Jiang</surname><given-names>HM</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Ai</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Xian</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Shih</surname><given-names>JW</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial</article-title><source>Lancet.</source><year>2010</year><volume>376</volume><issue>9744</issue><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61030-6</pub-id><pub-id pub-id-type="pmid">20728932</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T1</given-names></name><name><surname>Li</surname><given-names>SW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><article-title>Hepatitis E vaccine development: a 14 year odyssey</article-title><source>Hum Vaccin Immunother</source><year>2012</year><volume>8</volume><issue>6</issue><fpage>823</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.4161/hv.20042</pub-id><pub-id pub-id-type="pmid">22699438</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Thom K, Gilhooly P, McGowan K, Malloy K, Jarvis LM, Crossan C, Scobie L, Blatchford O, Smith-Palmer A, Donnelly MC, Davidson JS, Johannessen I, Simpson KJ, Dalton HR, Petrik J. Hepatitis E virus (HEV) in Scotland: evidence of recent increase in viral circulation in humans. Euro Surveill. 2018;23(12).</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.japantimes.co.jp/news/2018/02/01/national/world-first-womans-death-linked-hepatitis-e-infection-blood-transfusion-japanese-facility/">https://www.japantimes.co.jp/news/2018/02/01/national/world-first-womans-death-linked-hepatitis-e-infection-blood-transfusion-japanese-facility/</ext-link>. Accessed 17 June 2019.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vos</surname><given-names>AS</given-names></name><name><surname>Janssen</surname><given-names>MP</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name><name><surname>Hogema</surname><given-names>BM</given-names></name></person-group><article-title>Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands</article-title><source>Transfusion.</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/trf.13978</pub-id><pub-id pub-id-type="pmid">28144956</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamp</surname><given-names>C</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>J</given-names></name><name><surname>Baylis</surname><given-names>SA</given-names></name><name><surname>Bekeredjian-Ding</surname><given-names>I</given-names></name><name><surname>Chudy</surname><given-names>M</given-names></name><name><surname>Heiden</surname><given-names>M</given-names></name><name><surname>Henseler</surname><given-names>O</given-names></name><name><surname>Keller-Stanislawski</surname><given-names>B</given-names></name><name><surname>de Vos</surname><given-names>AS</given-names></name><name><surname>Funk</surname><given-names>MB</given-names></name></person-group><article-title>Impact of hepatitis E virus testing on the safety of blood components in Germany - results of a simulation study</article-title><source>Vox Sang</source><year>2018</year><volume>113</volume><issue>8</issue><fpage>811</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1111/vox.12719</pub-id><pub-id pub-id-type="pmid">30318777</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denner</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E virus (HEV)-the future</article-title><source>Viruses.</source><year>2019</year><volume>13</volume><issue>3</issue><fpage>11</fpage></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyrion</surname><given-names>Emmanuelle</given-names></name><name><surname>Trouve-Buisson</surname><given-names>Thibaut</given-names></name><name><surname>Pouzol</surname><given-names>Patricia</given-names></name><name><surname>Larrat</surname><given-names>Sylvie</given-names></name><name><surname>Decaens</surname><given-names>Thomas</given-names></name><name><surname>Payen</surname><given-names>Jean-Francois</given-names></name></person-group><article-title>Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient</article-title><source>Emerging Infectious Diseases</source><year>2017</year><volume>23</volume><issue>1</issue><fpage>146</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.3201/eid2301.160923</pub-id><pub-id pub-id-type="pmid">27983485</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>P</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Motamed</surname><given-names>D</given-names></name></person-group><article-title>Chronic hepatitis E in an immunocompetent patient: a case report</article-title><source>Hepatology, Hepatology</source><year>2014</year><volume>59</volume><issue>1</issue><fpage>347</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1002/hep.26636</pub-id><pub-id pub-id-type="pmid">23913727</pub-id></element-citation></ref></ref-list></back></article>